Drug Profile
Research programme: viral vaccines - Changchun Institute of Biological Products
Alternative Names: Bivalent hemorrhagic fever vaccine - Changchun Institute of Biological Products; Inactivated hepatitis A vaccine - Changchun Institute of Biological Products; Inactivated tick-borne encephalitis vaccine - Changchun Institute of Biological Products; Rabies vaccine - Changchun Institute of Biological ProductsLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Changchun Institute of Biological Products
- Class Hepatitis A vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Encephalitis virus infections; Hepatitis A; Rabies; Viral haemorrhagic fevers
Most Recent Events
- 22 Sep 2023 Preclinical development is ongoing in Encephalitis-virus-infections in China (Parenteral) (Changchun Institute of Biological Products website; September 2023)
- 22 Sep 2023 Preclinical development is ongoing in Hepatitis A in China (Parenteral) (Changchun Institute of Biological Products website; September 2023)
- 22 Sep 2023 Preclinical development is ongoing in Viral haemorrhagic fevers in China (Parenteral) (Changchun Institute of Biological Products website; September 2023)